NasdaqGS:WGSHealthcare
Will GeneDx Holdings' (WGS) Rising Revenue and Widening Losses Recast Its Profitability Narrative?
GeneDx Holdings Corp. has reported its past first-quarter 2026 results, with revenue rising to US$102.25 million from US$87.12 million a year earlier, while net loss widened to US$63.32 million and basic and diluted loss per share from continuing operations increased to US$2.16 from US$0.23.
The combination of stronger top-line performance and much higher losses raises questions about how GeneDx is balancing growth investments against its path toward profitability.
Now we will examine how...